Plasminogen activator inhibitor type 1 in diabetes and hypertension

Current Opinion in Endocrinology and Diabetes

Volumn 4, Issue 3, 1997, Pages 233-238

  Litchfield, W Reid ^a   Brown, Nancy ^b   Vaughan, Douglas E ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0005453518     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199706000-00009     Document Type: Article

References (38)

1. Rijken DC: Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillieres Clin Haematol 1995, 8:291-312.
2. Vaughan DE: Plasminogen activator inhibitor 1: molecular aspects and clinical significance. J Thromb Thrombol 1995, 2:187-193.
3. Lijnen HR, Collen D: Mechanisms of physiological fibrinolysis. Baillieres Clin Haematol 1995, 8:277-290.
4. Dawson S, Henney A: The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Arteriosclerosis 1992, 95:105-117.
5. Prins MH, Hirsh J: A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Am Heart J 1991, 122:545-551.
6. Ridker PM, Vaughan DE, Stamper MJ, Manson JAE, Hennekens CH: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993, 341:1165-1168.
7. Jansson J, Olofsson B, Nilsson TK: Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7 year follow-up. Circulation 1993, 88:2030-2034.
8. Munkvad S, Gram J, Jesperson J: A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 1990, 11:525-528.
9. Angleton P, Chandler WL, Schmer G: Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor. Circulation 1989, 79:101-106.
10. Grimaudo V, Hauert J, Bachmann F, Kruithof KO: Diurnal variation of the fibrinolytic system. Thromb Haemost 1988, 59:495-499.
11. McCarty MF: Hemostatic concomitants of syndrome X. Med Hypotheses 1995, 44:179-193.
12. Vague P, Raccah D, Scelles V: Hypofibrinolysis and the insulin resistance syndrome. Int J Obes Relat Metab Disord 1995, 19(suppl 1):S11-S15. A summary of various phenotypic features of the insulin resistance syndrome and how they influence PAI-1 levels. The authors review the strength of the association between PAI-1 and either insulin or triglyceride levels and discuss the fibrinolytic effects of interventional studies designed to decrease insulin resistance.
13. Mansfield MW, Stickland MH, Grant PJ: Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995, 74:842-847. A large study of type II diabetic patients that shows a strong correlation between PAI-1 and features of insulin resistance. The authors demonstrate that the interaction between PAI-1 and both triglycerides and glucose is altered by PAI-1 genotype.
14. Bastard J, Bruckert E, Robert J, Ankri A, Grimaldi A, Jardel C, Hainque B: Are free fatty acids related to plasma plasminogen activator inhibitor 1 in android obesity? Int J Obes Relat Metab Disord 1995, 19:836-838. A euglycemic hyperinsulinemic clamp study that showed PAI-1 to be correlated with obesity but not diabetes. The study suggested a relationship between elevated PAI-1 and insulin resistance at the level of lipid rather than glucose metabolism.
15. Gray RP, Mohamed-Ali V, Patterson DL, Yudkin JS: Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction. Thromb Haemost 1995, 73:261-267.
16. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS: Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995, 44:37-42. A study showing strong correlation between insulin resistance and PAI-1 activity. PAI-1 genotype influences basal PAI-1 levels and the relationship between triglycerides and PAI-1 activity.
17. Cigolini M, Targher G, Seidell JC, Tonoli M, Schiavon R, Agostino G, De Sandre G: Relationships of blood pressure to fibrinolysis: influence of anthropometry, metabolic profile and behavioural variables. J Hypertens 1995, 13:659-666. A cohort study of Italian men in which hypertension was associated with elevated PAI-1 levels. The study suggests that the association may be related to hyperinsulinemia and hypertriglyceridemia rather than elevated blood pressure.
18. Nordt TK, Sawa H, Fujii S, Sobel BE: Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995, 91:764-770.
19. DeSouza CA, Dengel DR, Rogers MA, Cox; K, Macko RF: The fibrinolytic system is not impaired in older men with hypertension. Hypertension 1996, 27:1053-1058. A study of the fibrinolytic system in hypertensive patients in which confounding factors such as cardiovascular disease, diabetes, and dyslipidemia were carefully controlled. The authors conclude that metabolic disorders that accompany hypertension, rather than elevated blood pressure, alter fibrinolysis.
20. Ito Y, Okeda T, Sato Y, Ito M, Sakata T: Plasminogen activator inhibitor-1 in nonobese subjects with non-insulin dependent diabetes mellitus. Proc Soc Exp Biol Med 1996, 211:287-291.
21. Trifiletti A, Barbera N, Pizzoleo MA, Lasco A, Lucifora S, Leone G, Soraci S, Pedulla M, Frisina N: Haemostatic variables in arterial hypertension. Haemostasia 1995, 25:237-240.
22. Jeng JW, Sheu HH, Jeng C, Huang S, Shieh S: Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 1996, 9:484-490.
23. Wall U, Jern C, Bergbrant A, Jem S: Enhanced levels of tissue-type plasminogen activator in borderline hypertension. Hypertension 1995, 26:796-800.
24. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J: Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990, 10:1067-1073.
25. Raccah D, Messt MC, Scelles V, Menard C, Juhan-Vague I, Vague P: Plasminogen activator inhibitor activity in various types of endogenous hypertriglyceridemia. Fibrinolysis 1993, 7:171-176.
26. Egan BM, Hennes MMI, Stepniakowski KT, O'Shaughnessy IMO, Kissebath AH, Goodfriend TL: Obesity hypertension is related more to insulin's fatty acid than glucose action. Hypertension 1996, 27(part 2):723-728.
27. Olson JAJ, Shiverick KT, Ogilvie S, Buhi WC, Raizada MK: Angiotensin-II induces secretion of plasminogen activator inhibitor 1 and tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Proc Natl Acad Sci U S A 1991, 8:1928-1932.
28. Vaughan OE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995, 95:995-1001. Angiotensin II induces dose- and time-dependent increases in PAI-1 antigen and mRNA in endothelial cells in vitro.
29. Feener EP, Northrup JM, Aiello LP, King GL: Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995, 95:1353-1362. Angiotensin II increases PAI-1 antigen, activity, and mRNA in rat vascular smooth muscle cells and rat endothelial cells in vitro.
30. Hamdan AD, Quist WC, Gagne JB, Feener EP: Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996, 93:1073-1078.
31. Kerins DM, Hao Q, Vaughan DE: Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995, 96:2515-2520. Angiotensin IV induces dose- and time-dependent increases in PAI-1 mRNA in cultured endothelial cells. These effects appear to be mediated through the angiotensin IV receptor.
32. Seljeflot I, Moan A, Kjeldsen S, Sandvik E, Arnesen H: Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 1996, 27:1299-1304.
33. Wright RA, Flapan AD, Alberti KGMM, Ludlum CA, Fox KAA: Effects of captopril on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994, 24:67-73.
34. Pfeffer MA, Braunwauld E, Moye LE, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992, 327:669-677.
35. Yusuf S, Pepine CJ, Garces C, Pouleur D, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B: Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992, 340:1173-1178.
36. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991, 11:183-190
37. Eriksson P, Kallin B, Van't Hoof FM, Bavenholm P, Hamsten A: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995, 92:1851-1855. The 4G allele of the PAI-1 promoter polymorphism is associated with higher PAI-1 activity in patients with coronary artery disease. These patients had a higher prevalence of the 4G allele than did population-based controls.
38. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ: Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 1997, 17:33-37. A large study in coronary angiography patients in which the number of 4G alleles was positively correlated with PAI-1. In addition, 4G/4G was associated with a history of myocardial infarction and a stronger correlation between triglycerides and PAI-1 levels.